>They promise to reveal data points with K_M curve at ASCO '09.<
One other piece of important data is probably the balance of post-TNFerade treatments between arms. Did more people on TNFerade progress and move to gemzar / tarceva as compared to the SOC?
It's just very suspicious that the clinical benefit arises 8-10 months after drug injection. Post-treatment therapy becomes a big question in such scenarios, imo.
Market Data 
Markets 
AI
